Clinical Trials
19 trialsNCT05384626 2026-05-27
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
Phase 1/2 Recruiting
NCT05208047 2026-05-22
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Phase 3 Active not recruiting
NCT05355701 2026-05-14
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT04067336 2026-05-13
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1/2 Active not recruiting
NCT02365597 2026-05-08
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05646862 2026-05-06
INAVO121
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07426757 2026-04-07
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Pfizer
Phase 1 Not yet recruiting
NCT07340190 2026-04-02
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Novartis
Phase 1 Not yet recruiting
NCT03600883 2026-03-16
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
Phase 1/2 Active not recruiting
NCT03016819 2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3 Recruiting
NCT07408193 2026-02-20
The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.
National and Kapodistrian University of Athens
Phase EARLY_PHASE1 Not yet recruiting
NCT04973163 2026-02-17
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07235748 2026-02-17
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Servier
Phase 1 Completed
NCT06575933 2026-02-11
MK-1084-009
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT04557449 2025-10-01
CDK4i
Pfizer
Phase 2 Active not recruiting
NCT06547164 2025-09-04
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants
AstraZeneca
Phase 1 Completed
NCT04051827 2025-07-28
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Takeda
Phase 1 Completed
NCT03436485 2025-07-22
CYPIDES
Orion Corporation, Orion Pharma
Phase 1/2 Active not recruiting